FOXO4-DRI Human Trials: Status, Evidence Gaps, and What to Watch (2026)

On October 14, 2026, we searched ClinicalTrials.gov separately for “FOXO4-DRI,” “FOXO4 DRI” and “Proxofim.” Each returned no studies. A broader “FOXO4” search returned NCT07494565, a lymphoma study of celecoxib plus R-CHOP, not a trial of this peptide.

We also searched PubMed using the compound names, reviewed the returned reports and checked the original Baar paper, whose abstract uses the broader phrase “FOXO4 peptide.” We did not identify a human treatment trial. Human-cell experiments, patient tissue analyses and reviews must not be counted as trials of administration to people.

ClinicalTrials.gov is one registry. Trials may use other registries or different intervention names, and unpublished or unregistered work may be missed. A search with no matching record therefore supports a bounded search result, not a claim that no trial exists anywhere or that every legitimate study must be listed on this particular registry.

Examples of the preclinical record include the original fibroblast and mouse experiments (PMID 28340339), aged-mouse Leydig-cell work (PMID 31959736), and pulmonary fibrosis models (PMID 35510614; PMID 37074394). Human cells have been studied outside the body: expanded healthy-donor chondrocytes (PMID 33996787), keloid fibroblasts and organ cultures (PMID 39994346), and endothelial cultures alongside mouse vascular-aging experiments (PMID 41625068).

Benefits are not uniform across models. Born et al. reported worsened pulmonary hemodynamics and endothelial-cell loss with FOXO4-DRI in mice (PMID 36515093). See the safety review. This list is illustrative, not an exhaustive count of papers or independent laboratories.

The reviewed primary studies do not establish human pharmacokinetics, a safe or effective human dose, or long-term clinical outcomes. Some mouse models report tolerability, while another reports harm. A publicly accessible, regulatory-grade toxicology package was not identified in this review; that does not establish that no unpublished work exists.

These are evidence gaps, not verified explanations of every sponsor’s development decisions. Claims about why a trial has not started or which molecule a company will advance require separate current evidence.

Human senolytic research includes drugs other than FOXO4-DRI. For example, Farr et al. tested dasatinib plus quercetin in a randomized trial in postmenopausal women (PMID 38956196); the primary bone-resorption endpoint was negative overall, with exploratory subgroup findings. Such trials establish evidence for their own interventions and populations, not for FOXO4-DRI.

Useful evidence would include a public trial record identifying the exact intervention, sponsor, population, oversight and study status; a measured pharmacokinetic profile; and dose-related toxicology. A registry entry would be a signal to review the protocol and status, not proof of recruitment, successful completion or efficacy.

Registries and literature change. This page records the search performed on October 14, 2026; its conclusion is limited to what that search identified.